News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Elan Corporation PLC (ELN) Fuels Buyout Plans With $130 Million R&D Spinout, Unit Will Have Around 80 Staffers


8/13/2012 6:55:57 AM

Ireland's Elan (ELN.I) said on Monday it would spin off its Neotope drug discovery business platform as a separate public company in a move making Elan immediately profitable. The decision to split the company comes hard on the heels of the failure of an experimental Alzheimer's drug being developed with Pfizer (PFE.N) and Johnson & Johnson (JNJ.N), although Chief Executive Kelly Martin said it had been planned for more than a year. The move may fuel speculation that Elan, shorn of its loss-making research arm, will be a more attractive takeover target for U.S. biotech company Biogen Idec (BIIB.O), with which it markets the multiple sclerosis drug Tysabri.

Read at Reuters
Read at News Release
Read at Street Insider
Read at News Release
Read at RTE News Online

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES